Fulgent Genetics to Present at the 25th Annual Credit Suisse Healthcare Conference

- October 25th, 2016

Fulgent Genetics today announced that Ming Hsieh, its Chairman and Chief Executive Officer, Dr. Harry Gao, its Chief Science Officer, and Paul Kim, its Chief Financial Officer, are scheduled to present at the 25th Annual Credit Suisse Healthcare Conference.

Fulgent Genetics, Inc. (Nasdaq:FLGT) (“Fulgent Genetics” or the “company”) today announced that Ming Hsieh, its Chairman and Chief Executive Officer, Dr. Harry Gao, its Chief Science Officer, and Paul Kim, its Chief Financial Officer, are scheduled to present at the 25th Annual Credit Suisse Healthcare Conference at the Phoenician hotel in Scottsdale, Arizona on Monday, November 7, 2016 at 4:00 PM MST (3:00 PM PST).

The live audio webcast and accompanying slide presentation can be accessed in the Investor Relations section of the company’s website, www.fulgentgenetics.com, and an audio replay of the webcast will remain available on the company’s website through December 7, 2016.
About Fulgent Genetics, Inc.
Fulgent Genetics is a rapidly growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu while maintaining accessible pricing, high accuracy, and competitive turnaround times. The company believes its current test menu, which includes more than 18,000 single-gene tests and more than 200 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.

Investor Contacts
The Blueshirt Group
Bob Jones, 212-871-5570, bob@blueshirtgroup.com
Chris Danne, 415-217-5865, chris@blueshirtgroup.com

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply